About 42 results for "sarabjit kour nangra"

US marketing to get tough for Ranbaxy Laboratories

Tags: Ranbaxy Laboratories | Arun Sawhney | Ranbaxy Atorvastatin | Sarabjit Kour Nangra | US Business Ranbaxy Laboratories may find it tough to revive its struggling US business in the face of accepting federal charges of selling adulterated ... Financial Express, 1 week ago

Agreeing to adulterated-drug charges to make US marketing tough for Ranbaxy [Financial Express (India)] - Pharmacy Choice, 1 week ago

Ranbaxy shares recover, gain 4% - Business Today India, 1 week ago

More from: Moneycontrol.com, Pharmacy Choice...and 1 other sources

[x]

After swallowing bitter pill, Ranbaxy set to revive sales in US

In an affirmative sign, Ranbaxy shrugged off early losses after Monday's ruling to steadily climb 1.75 percent to Rs 463.45 on Wednesday on the Bombay Stock Exchange after analysts said the settlement of the US lawsuit clears a big overhang on the ...

Firstpost.com, 6 days ago

Silence on Ranbaxy supply resumption a worry

Related to : Ranbaxy Laboratories Ltd Ranbaxy Laboratories Ltd BSE 14 May 13 | 12:00 AM 455.50 15.95 (3.63%) NSE 14 May 13 | 12:00 AM 455.65 15.95 (3.63%) For Ranbaxy Laboratories, the worst might not be over yet. Now, the Street is seeking a ...

Smart Investor, 1 week ago

Indian Express

Ranbaxy to pop rebuild pill

Mumbai, May 14: The real challenge for Ranbaxy begins now after it admitted felony charges and agreed to pay $500 million to settle charges that it had marketed adulterated drugs in the US made at its two Indian plants. Analysts say the Daiichi ...

Calcutta Telegraph, 1 week ago Ranbaxy Laboratories shares down over 4% Indian Express, 1 week ago Ranbaxy shares wipe off early losses Hindu Business Line, 1 week ago Ranbaxy shares down over 4% ZeeNews.com, 1 week ago

ZeeNews.com

...shares end nearly 4% higher.

Shares of Ranbaxy Laboratories recovered from early losses and settled nearly 4 per cent higher on hopes that settlement of its long lawsuit in the US would be positive for drug maker the in the long term. The stock opened weak on the BSE and fell ...

New Delhi Pioneer, 1 week ago Ranbaxy recovers lost ground; shares end nearly 4% higher ZeeNews.com, 1 week ago Ranbaxy recovers ground; shares end 4% higher Economic Times, 1 week ago

Ranbaxy settles US case for $500 mn, shares spurt 3.6%

Shares of drug maker Ranbaxy Laboratories ended 3.6% up at Rs. 455.50 on Tuesday after crashing 4% in early trade on the Bombay Stock Exchange following a $500-million (about Rs. 2,750 crore) fine imposed by US authorities on the company for selling ...

Hindustan Times, 1 week ago $500 mn US settlement positive for Ranbaxy: Analysts Economic Times, 1 week ago Ranbaxy settles US case for 500 mn shares spurt 36 Hindustan Times, 1 week ago

ZeeNews.com

Angel Broking maintains 'Neutral' on Dr Reddy's post Q4 nos

Dr Reddy's Laboratories , an integrated global pharmaceutical company, today reported growth of 66.59% in its consolidated fourth quarter net profit, helped by strong growth in other income. It earned profit of Rs 5.71 billion for the quarter ended Mar. 31, ...

Myiris, 1 week ago Anji Reddy's absence not to change DRL's direction Economic Times, 2 months ago No major directional changes seen at Dr Reddy's: Analysts Hindu Business Line, 2 months ago

More from: , Economic Times...and 1 other sources, Economic Times...and 1 other sources

[x]

Indian Express

Ranbaxy shares down over 4% in early trade

After making a weak opening, shares of the company further tanked 4.22 per cent to Rs 421 on the BSE. (Reuters) Related Top Stories Shares of Ranbaxy Laboratories today fell by over 4 per cent in early trade, after US subsidiary of the company ...

Indian Express, 1 week ago

Ranbaxy net profit plunges 90%

Related to : Ranbaxy Laboratories Ltd Ranbaxy Laboratories Ltd BSE 08 May 13 | 12:00 AM 443.80 -12.7 (-2.78%) NSE 08 May 13 | 12:00 AM 443.85 -13.45 (-2.94%) For the quarter ended March, drug maker Ranbaxy Laboratories consolidated net profit ...

Smart Investor, 1 week ago Ranbaxy net dips 90% on losing Lipitor generic Financial Chronicle, 1 week ago

Lupin Q4 net profit surges 162%

Drug maker Lupin Ltd posted a record profit of Rs.408 crore for the quarter ended March, up 162% from a year ago, benefiting mainly from strong demand in the US. Revenue increased 34.42% to Rs.2,585.82 crore. "We have had a great quarter and a ...

Individual.com, 2 weeks ago

Prev | Next

About 42 results for "sarabjit kour nangra"

Related Queries - sarabjit kour nangra